Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

findings from the measurement of disability weights in China with an emphasis on the impact of disease burden.

2.

Maintenance Rituximab Improves Survival in Elderly MRD-Negative MCL Patients.

3.

Understudied mental health challenges among caregivers of cancer patients: A call for targeted support

4.

A Texas study found that the majority of pancreatic cancer patients do not receive life-saving surgery.

5.

According to a study, taking part in a clinical trial for cancer may not actually increase survival.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot